Ciaccio P J, Shen H, Kruh G D, Tew K D
Department of Pharmacology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA.
Biochem Biophys Res Commun. 1996 May 6;222(1):111-5. doi: 10.1006/bbrc.1996.0706.
Chronic exposure to ethacrynic acid of a subcloned HT29 human colon cancer cell line produces a 3- to 4-fold increase in the level of resistance to this agent. The resistant cells (HT6-8) have an enhanced capacity to metabolize the parent drug and efflux it from the cell. This is reflected in a 5-fold enhanced decompositioning rate constant for ethacrynic acid in HT6-8 (3.47 x 10-3 min-1) versus wild type cells (1.58 x 10-2 min-1). We observed that the glutathione conjugate of ethacrynic acid is an effective competitive inhibitor for binding to the multidrug resistance-associated protein by [35S]azidophenacyl-glutathione, a photoaffinity analog of glutathione. In addition, the HT6-8 cells overexpressed multidrug resistance-associated transcript 2- to 3-fold. These results suggest that resistance to ethacrynic acid results from a concerted, coordinate increase in defense mechanisms which detoxify the drug and remove its conjugate via plasma membrane efflux.
对亚克隆的HT29人结肠癌细胞系长期暴露于依他尼酸会使其对该药物的抗性水平提高3至4倍。耐药细胞(HT6-8)代谢母体药物并将其排出细胞的能力增强。这体现在HT6-8中依他尼酸的分解速率常数(3.47×10⁻³ min⁻¹)比野生型细胞(1.58×10⁻² min⁻¹)提高了5倍。我们观察到依他尼酸的谷胱甘肽结合物是[³⁵S]叠氮苯甲酰谷胱甘肽(谷胱甘肽的光亲和类似物)与多药耐药相关蛋白结合的有效竞争性抑制剂。此外,HT6-8细胞中多药耐药相关转录本的表达量过表达了2至3倍。这些结果表明,对依他尼酸的抗性源于防御机制的协同、协调增加,这些机制使药物解毒并通过质膜外排去除其结合物。